Cabozantinib response in a NSCLC patient harboring both MET exon 14 skipping mutation and secondary RET fusion: A case report
JTO Clinical and Research Reports(2024)
摘要
MET exon 14 skipping mutation has emerged as a new oncogenic driver in non small cell lung cancer (NSCLC) with available targeted therapies, including FDA approved inhibitors capmatinib and tepotinib. Potential resistance mechanisms are beginning to be described and include several on-target and off-target mutations. Herein, we report an emergent secondary RET fusion in a patient with a primary MET exon 14 skipping mutation that progressed on capmatinib after initial response. Subsequently, this patient received both a RET inhibitor (selpercatinib) followed by another MET targeted treatment (tepotinib) without clinical benefit. Thereafter, cabozantinib, a multikinase inhibitor with activity against RET and MET was started with a rapid clinical and radiological benefit.
更多查看译文
关键词
MET exon 14,RET fusion,TKI,non small cell lung cancer,case report
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要